Search

Search Constraints

You searched for: Author/Creator Pappas, Peter G

Search Results

2. 123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI). (4th December 2021)

3. 144. MSG-15: Pharmacokinetic (PK), Adverse Events (AEs), and Tolerability Data from an Open Label Randomized Clinical Trial (RCT) Comparing Oral Suba-itraconazole (SUBA-ITC) to Conventional Itraconazole (C-ITC) for Treatment of Endemic Mycosis (EM). (31st December 2020)

4. 231. Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis. (15th December 2022)

7. Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27–30, 2018, Big Sky, Montana, a proposed global research agenda. (14th May 2020)

9. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. (5th August 2020)

10. Coronavirus Disease 2019–Associated Invasive Fungal Infection. (16th November 2021)